3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s78, 2022. DOI: 10.25251/skin.6.supp.78. Disponível em: https://skin.dermsquared.com/skin/article/view/1836. Acesso em: 9 mar. 2026.